Amgen’s $3.7B ChemoCentryx acquisition adds a new piece to autoimmune strategy
Amgen is shelling out nearly $4 billion to acquire ChemoCentryx, the latest in a string of M&A moves for the pharmaceutical giant and one that helps the company expand its approach to treating autoimmune diseases, and potentially also cancer. ChemoCentryx’s main asset is Tavneos, a treatment for ANCA-associated vasculitis, an autoimmune disease that damages organs, … Read more